Last updated: August 4, 2026
Omeros Corporation sued Sandoz Inc. in the U.S. District Court for the District of Delaware after Sandoz filed an abbreviated new drug application for a generic version of Omidria, Omeros’s intraocular phenylephrine and ketorolac product. The case concerned U.S. Patent Nos. 8,778,962 and 9,066,856, which covered the drug combination and its use during cataract surgery. The Federal Circuit later affirmed the district court’s principal rulings in Omeros’s favor, leaving Sandoz unable to launch its ANDA product before the asserted patent protection expired or the parties otherwise resolved their dispute. [1-3]
What drug and patents were at issue in Omeros v. Sandoz?
The litigation concerned Omidria, a sterile intraocular solution containing phenylephrine hydrochloride and ketorolac tromethamine. Omeros markets Omidria for use during cataract surgery and intraocular lens replacement procedures.
| Item |
Detail |
| Brand drug |
Omidria |
| Active ingredients |
Phenylephrine hydrochloride and ketorolac tromethamine |
| Dosage form |
Intraocular irrigation solution |
| Therapeutic use |
Maintaining pupil dilation and reducing ocular pain and inflammation during surgery |
| NDA holder |
Omeros Corporation |
| ANDA filer |
Sandoz Inc. |
| District court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:17-cv-00799 |
| Asserted patents |
U.S. Patent Nos. 8,778,962 and 9,066,856 |
| Federal Circuit decision |
Omeros Corp. v. Sandoz Inc., 903 F.3d 1356 (Fed. Cir. 2018) |
The patents claimed formulations and methods combining phenylephrine and ketorolac at concentrations suitable for use during ophthalmic surgery. The commercial rationale was that the combination could maintain mydriasis while addressing pain and inflammation without requiring separate administration of the two active ingredients. [1, 2]
When did Omeros file the Sandoz patent lawsuit?
Omeros filed the action in 2017 after receiving notice of Sandoz’s Paragraph IV certification. Sandoz’s ANDA certification represented that the relevant Omeros patents were invalid, unenforceable, or would not be infringed by the proposed generic product.
The lawsuit triggered the Hatch-Waxman litigation framework. Under 21 U.S.C. § 355(j)(5)(B)(iii), the filing of the action imposed an FDA approval stay on Sandoz’s ANDA for up to 30 months, subject to earlier termination or court action. [4]
The case was assigned civil action No. 1:17-cv-00799 in the District of Delaware. Delaware is a major venue for pharmaceutical patent litigation because many drug companies are incorporated there and because the district has substantial experience with ANDA disputes.
What patents protected Omidria against Sandoz?
U.S. Patent No. 8,778,962
The ’962 patent covered aspects of the phenylephrine-ketorolac combination used in ophthalmic surgery. The asserted claims addressed the composition and concentration relationship between the two active ingredients.
The patent was important because it linked the active ingredients in a single ophthalmic formulation. Sandoz’s proposed product was designed to correspond to the same commercial combination, creating a direct infringement dispute rather than a peripheral formulation challenge.
U.S. Patent No. 9,066,856
The ’856 patent covered methods involving administration of the phenylephrine and ketorolac combination during cataract or related ophthalmic surgery. The method claims focused on maintaining pupil dilation and controlling surgical effects through administration of the claimed composition.
The asserted patent estate therefore included both product-oriented and method-oriented protection:
| Protection category |
Patent relevance |
| Composition protection |
The combined phenylephrine and ketorolac ophthalmic formulation |
| Concentration protection |
The concentration ranges and relative amounts of the active ingredients |
| Method-of-use protection |
Use during cataract surgery and related procedures |
| Commercial product protection |
Coverage directed at the same active combination used in Omidria |
What were Sandoz’s Paragraph IV arguments?
Sandoz challenged the asserted claims on infringement and validity grounds. The principal issues included:
- Whether the proposed ANDA product met the claim limitations concerning the active ingredients and their concentrations.
- Whether the asserted claims were obvious in view of prior art involving phenylephrine, ketorolac, ophthalmic irrigation solutions, and cataract surgery.
- Whether the prior art provided a reason to combine the two active ingredients in the claimed formulation.
- Whether the claimed combination produced unexpected results sufficient to support nonobviousness.
- Whether the claimed methods were adequately supported by the patent disclosures.
Sandoz’s central obviousness position was that the individual components and their ophthalmic uses were known, making the combination an expected formulation choice for a skilled artisan. Omeros argued that the prior art did not provide a sufficient reason to combine the agents in the claimed concentrations or with a reasonable expectation of achieving the claimed surgical benefits. [1, 2]
How did the District of Delaware decide the case?
The district court ruled for Omeros on the principal patent issues. The court found that Sandoz’s proposed ANDA product would infringe the asserted claims and rejected Sandoz’s invalidity challenges.
The district court’s analysis focused on the technical relationship between the claimed formulation and the surgical use. The court treated the claimed concentrations and combination as legally significant limitations rather than as routine optimization variables. The court also considered evidence concerning the formulation’s ability to maintain pupil dilation and provide the intended ophthalmic effects.
The resulting judgment prevented Sandoz from obtaining FDA approval for a product that would infringe the asserted claims during the remaining patent term.
What did the Federal Circuit decide in Omeros v. Sandoz?
The U.S. Court of Appeals for the Federal Circuit affirmed the district court’s principal judgment in 2018. The appellate decision addressed claim construction, infringement, and obviousness.
The Federal Circuit agreed that Sandoz’s ANDA product fell within the relevant patent claims. It also upheld the finding that the asserted claims were not invalid for obviousness.
The decision applied the established obviousness framework under 35 U.S.C. § 103. The court considered whether a skilled artisan would have had a reason to combine the relevant prior-art teachings and whether the evidence supported a reasonable expectation of success. The court did not treat the existence of the individual active ingredients in the prior art as sufficient by itself to establish obviousness.
The ruling was significant for the Omidria patent estate because it preserved the asserted composition and method claims against the first major ANDA challenge in the docket. [1]
What was the final litigation outcome?
The final reported appellate outcome was favorable to Omeros:
| Issue |
Outcome |
| ANDA product infringement |
Sandoz’s proposed product was found to infringe the asserted claims |
| Obviousness |
Asserted claims were upheld against the obviousness challenge |
| Patent enforceability |
No adverse enforceability ruling appears in the Federal Circuit decision |
| FDA approval timing |
The litigation blocked approval during the applicable patent-protection period |
| Federal Circuit disposition |
District court judgment affirmed |
The case did not establish that every Omidria-related patent would withstand every later challenge. Its effect was limited to the patents and claims asserted against Sandoz in that proceeding.
What was the Orange Book status of Omidria?
Omidria was listed in the FDA Orange Book with patent information submitted by the NDA holder. The asserted patents were part of Omeros’s listed patent position for the product at issue in the ANDA litigation. Orange Book listing creates the statutory framework for ANDA applicants to submit Paragraph IV certifications and for NDA holders to bring infringement litigation. [4, 5]
Orange Book listings do not independently establish patent validity or infringement. They identify patents that the NDA holder represents as covering the approved drug, its formulation, or an approved method of use.
For commercial analysis, the relevant distinction is:
- Orange Book listing creates the Hatch-Waxman certification trigger.
- A Paragraph IV notice creates the basis for an infringement action.
- A favorable judgment can block approval or commercial launch.
- Patent expiration, a settlement license, or a successful invalidity or noninfringement ruling can remove the barrier.
When did Omidria lose regulatory exclusivity?
Omidria received FDA approval in 2014. Its five-year new chemical entity exclusivity period generally protected the NDA from submission of an ANDA relying on the drug’s approval until 2019. That regulatory exclusivity was separate from the patent rights asserted against Sandoz. [5]
| Exclusivity type |
Approximate protection |
| FDA approval |
2014 |
| NCE exclusivity |
Approximately five years, ending in 2019 |
| Patent protection |
Extended beyond NCE exclusivity under the listed patents |
| ANDA pathway after NCE period |
Available subject to patent certifications and litigation |
The end of NCE exclusivity did not authorize immediate generic launch. Sandoz still had to address the listed patents, and the Paragraph IV litigation created an FDA approval stay.
What were the patent expiration dates?
The asserted Omidria patents had patent-term dates extending materially beyond the end of the product’s NCE exclusivity. Public patent records and FDA listing data should be used together when assessing expiration because terminal disclaimers, patent-term adjustment, patent-term extension, and corrected listing data can affect the operative date. [3, 5]
The relevant commercial point in the Sandoz case was that the asserted patents remained enforceable after the regulatory exclusivity period ended. That separation allowed Omeros to preserve a patent-based barrier against Sandoz even after the five-year FDA exclusivity period had lapsed.
What patent litigation affected Omidria after the Sandoz case?
The Sandoz action should be analyzed separately from later Omidria litigation involving other ANDA applicants and later-issued patents. A favorable result against one ANDA filer does not automatically resolve:
- Later-issued formulation patents.
- Separate method-of-use claims.
- Challenges by other generic manufacturers.
- Patent-term or Orange Book listing disputes.
- Settlement-based launch licenses.
- Products with different concentrations, excipients, container systems, or labeling.
Omeros’s broader patent strategy included layered protection around the active combination, ophthalmic delivery, concentration ranges, and surgical use. The strength of that strategy depended on whether later challengers could design around the asserted claims or attack them with different prior-art combinations.
How strong was Omeros’s patent estate after the Sandoz ruling?
The Sandoz result gave Omeros meaningful litigation leverage for three reasons.
First, the asserted claims covered the commercial active combination directly. Sandoz was not challenging a distant manufacturing process or a narrow side use. Its proposed product was directed to the same phenylephrine-ketorolac concept.
Second, the Federal Circuit affirmed the nonobviousness ruling. That reduced the immediate risk that the core claims would be invalidated based on the cited prior art.
Third, the patent estate extended beyond the period of FDA NCE exclusivity. Omeros therefore retained a patent-based strategy after generic applicants became eligible to file ANDAs.
The estate was not invulnerable. Generic applicants could still pursue inter partes review, district court invalidity defenses, noninfringement theories, labeling modifications, or design-around formulations. Patent strength also varied by claim type. Composition claims generally provided stronger product-level leverage than narrow method-of-use claims if the generic label omitted the patented indication.
What generic entry risks existed for Sandoz?
Sandoz faced four principal entry barriers:
- A court finding that the ANDA product infringed the asserted claims.
- The continuing term of the ’962 and ’856 patents.
- The FDA approval stay caused by the Paragraph IV litigation.
- The risk that a commercial launch before resolution would expose Sandoz to damages and injunctive relief.
A generic launch scenario would have required one of the following:
- Patent expiration.
- A license or settlement permitting an earlier launch.
- Reversal of the infringement or validity judgment.
- A noninfringing ANDA amendment.
- A successful challenge to the relevant Orange Book listing or patent scope.
The Federal Circuit ruling eliminated the most favorable immediate scenario for Sandoz: approval and launch based on a successful invalidity or noninfringement defense.
What is the business significance of the case for Omeros?
The case protected Omeros’s ability to maintain Omidria revenue after regulatory exclusivity ended. Omidria was a commercial product with concentrated exposure to U.S. ophthalmic surgery. A first generic launch could have produced rapid price erosion because the product’s active ingredients and dosage form were closely aligned with the branded product.
The decision also strengthened Omeros’s position in negotiations with other ANDA filers. A judgment affirming infringement and validity increases the expected cost of a competing generic’s litigation and reduces the attractiveness of an at-risk launch.
The commercial value depended on the remaining patent term, the number of potential ANDA entrants, the availability of alternative intraocular products, reimbursement conditions, and any later settlement licenses. The Sandoz judgment alone did not guarantee continued market exclusivity through every later-issued patent.
Key Takeaways
- Omeros sued Sandoz in the District of Delaware over a Paragraph IV ANDA challenge to Omidria.
- The case involved U.S. Patent Nos. 8,778,962 and 9,066,856.
- Omidria contains phenylephrine and ketorolac for use during ophthalmic surgery.
- The district court found infringement and upheld the asserted claims against Sandoz’s validity challenge.
- The Federal Circuit affirmed the principal judgment in 2018.
- Omidria’s NCE exclusivity ended before the asserted patent protection, making the patents commercially important after 2019.
- The decision blocked Sandoz’s proposed generic pathway during the relevant patent term.
- The ruling did not automatically resolve later patents, later ANDA challengers, or later settlement-based launch rights.
FAQs
Did Sandoz win invalidity of the Omidria patents?
No. The asserted claims survived Sandoz’s principal obviousness challenge, and the Federal Circuit affirmed the district court’s judgment favorable to Omeros.
Which active ingredients were covered by the Omidria litigation?
The litigation concerned phenylephrine hydrochloride and ketorolac tromethamine in a combined ophthalmic solution.
Was Omidria protected by FDA exclusivity after 2019?
The five-year NCE exclusivity period ended approximately in 2019. Continued protection depended on patents, not NCE exclusivity.
Could Sandoz launch a noninfringing Omidria generic after the decision?
Only if its product avoided the asserted claims, obtained a license, launched after patent expiration, or prevailed in a later proceeding involving different claims or patents.
Did the Omeros v. Sandoz decision cover every Omidria patent?
No. The judgment applied to the asserted patents and claims in civil action No. 1:17-cv-00799. Later-issued patents and separate litigation required independent analysis.
References
- Omeros Corp. v. Sandoz Inc., 903 F.3d 1356 (Fed. Cir. 2018).
- Omeros Corp. v. Sandoz Inc., No. 1:17-cv-00799, U.S. District Court for the District of Delaware.
- United States Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent Nos. 8,778,962 and 9,066,856. https://patentcenter.uspto.gov/
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
